SE Wenzel - Prostaglandins, Leukotrienes & Essential Fatty Acids, 2003 - Elsevier Leukotrienes (LT), both the cysteinyl LTs, LTC 4 , LTD 4 and LTE 4 , as well as
LTB 4 have been implicated in the clinical course, physiologic changes, and
pathogenesis of asthma. The cysteinyl LTs are potent bronchoconstrictors, ... Cited by 49 - Related articles - All 10 versions
J Claria, M Romano - Current pharmaceutical design, 2005 - ingentaconnect.com Abstract: Eicosanoids are potent biologically active arachidonic acid-derived
lipid mediators that are intimately involved in inflammation and cancer.
Cyclooxygenase (COX), the key enzyme in prostaglandin (PG) biosynthesis, ... Cited by 38 - Related articles - BL Direct - All 4 versions
V Capra, MD Thompson, A Sala, DE Cole, G … - Medicinal research reviews, 2007 - interscience.wiley.com It is also possible that your web browser is not configured or not able to
display style sheets. In this case, although the visual presentation will be
degraded, the site should continue to be functional. We recommend using the ... Cited by 34 - Related articles - BL Direct - All 3 versions
G Riccioni, T Bucciarelli, B Mancini, C Di Ilio, … - Current medicinal chemistry, 2007 - ingentaconnect.com Cysteinyl leukotrienes (Cys-LTs) are lipoxygenase products derived from the
metabolism of arachidonic acid (AA). Since the 1960s these were identified as
slow reacting substances of anaphylaxis (SLR-A) [1] and linked to bronchial ... Cited by 19 - Related articles - BL Direct - All 4 versions
K Kassahun, K Skordos, I McIntosh, D … - Chem. Res. Toxicol, 2005 - pubs.acs.org Zafirlukast is a leukotriene antagonist indicated for the treatment of mild to
moderate asthma, but the drug has been associated with occasional idiosyncratic
hepatotoxicity. Structurally, zafirlukast is similar to 3-methylindole ... Cited by 17 - Related articles - All 5 versions
J Jampilek, M Dolezal, V Opletalova, J Hartl - Current medicinal chemistry, 2006 - ingentaconnect.com Abstract: Leukotrienes play an important role in the inflammatory process
accompanying allergic diseases of respiratory, gastrointestinal and
dermatological systems. Leukotrienes are generated from arachidonic acid as ... Cited by 15 - Related articles - BL Direct - All 5 versions
- ►adisonline.com [PDF] PNR Dekhuijzen, PP Koopmans - Clinical pharmacokinetics, 2002 - ingentaconnect.com Abstract Zafirlukast is a cysteinyl leukotriene type 1 receptor antagonist that
causes bronchodilation and has anti-inflammatory properties. Clinical efficacy
has been demonstrated when using oral doses of 20 to 40mg twice daily. The ... Cited by 15 - Related articles - BL Direct - All 6 versions
KH Liu, YM Lee, JH Shon, MJ Kim, SS Lee, YR … - Xenobiotica, 2004 - informahealthcare.com 5.86 Æ 0.08 mM, respectively. 3. Pranlukast had no effect on CYP2C19-catalysed
S-mephenytoin 40-hydroxylation or CYP3A4-catalysed midazolam 1-hydroxylation.
However, zafirlukast showed minor inhibition of these reactions. Neither ... Cited by 12 - Related articles - BL Direct - All 8 versions
GC Actis, A Morgando, M Lagget, E David, M … - Journal of Hepatology, 2001 - Elsevier The initial observation [1] of the occurrence of sub-massive hepatic necrosis in
three North-American patients receiving the leukotriene receptor antagonist,
zafirlukast, for allergic asthma, has not been followed by any further ... Cited by 12 - Related articles - BL Direct - All 6 versions
